Chan Whiting
Profile
Chan Whiting worked as the Director & Head-Immune Monitoring at Aduro BioTech, Inc. and as the Senior Vice President-Research & Development at Tempest Therapeutics, Inc. before obtaining an undergraduate and doctorate degree from the University of California, Los Angeles.
Former positions of Chan Whiting
| Companies | Position | End |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-08-31 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Training of Chan Whiting
| University of California, Los Angeles | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Chan Whiting
